MedPath

Assessment of Urinary Diversions Outcomes Post Radical Cystectomy in Asyut University Urology Hospital

Conditions
Bladder Cancer
Registration Number
NCT04406168
Lead Sponsor
Assiut University
Brief Summary

Radical cystectomy (RC) for bladder cancer requires reconstruction of the lower urinary tract. Both continent and incontinent diversions are available for urinary reconstruction after RC. Types of urinary diversions include ( ileal conduit, uretero-cutaneous, ureterosigmoidostomy and orthotopic bladder) The decision process is complex and involves consideration of issues related to cancer stage, patient comorbidities, treatment needs, and patient desires related to Quality of life and intraoperative findings. Outcomes of urinary diversions include 1- survival rate (cancer specific or overall survival). 2- Oncological failure (local, distant or LNs). 3- Complications (perioperative, intraoperative or post-operative).

In this study, all these outcomes will be analyzed.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
40
Inclusion Criteria
  • * All patients underwent radical cystectomy more than 1 year
Exclusion Criteria
  • incomplete data
  • patients underwent RC outside urology department and presented for treatment of complications.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Rate of patients presented by complications1 year post operative

such as (change from baseline of the SCR - urinary tract infections - stone formation - stricture at site of anastomosis or stromal stenosis )

Survival rate (overall survival & cancer specific)1 year post operative

patient live post operative

Rate of patients developed recurrence1 year post operative

recurrence of cancer

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Assiut University

🇪🇬

Assiut, Elgam3a, Egypt

Assiut University
🇪🇬Assiut, Elgam3a, Egypt
tarek m elgamaal
Contact

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.